DRREDDYS LABORATORIES

BSE: 500124 28 Sep 2025

Healthcare

₹ 1301.85

Dr. Reddy's Laboratories Ltd., specializes in Pharmaceuticals within the Healthcare sector.

DRREDDYS LABORATORIES

BSE: 500124 28 Sep 2025

Healthcare

₹ 1301.85

Dr. Reddy's Laboratories Ltd., specializes in Pharmaceuticals within the Healthcare sector.

Book Value

402.0

Dividend Yield

0.64%

Debt to Equity

0.14

Stock P/E

18.4

Market Cap

1,04,585 Cr

DRREDDYS LABORATORIES - Share Price & Details

Market Cap

₹1,04,585

High /Low

1,406 / 1,020

Stock P/E

18.4

Book Value

₹402.0

Dividend Yield

0.64

ROCE

22.7

ROE

₹18.0

Face Value

1.0

PEG Ratio

0.48

EVEBITDA

₹10.9

Debt

4,677

CMP / FCF

43.3

Debt to equity

₹0.14

NP Ann

5,725

High price all time

1,421

Piotroski score

₹2.0

Graham Number

785.0

No. Eq. Shares

83.5

Net CF

₹749

Net profit

5,743

Price to book value

3.12

Interest Coverage

₹26.2

Low price all time

60.5

Industry PE

33.0

Reserves

₹33,466

Free Cash Flow

₹1,327

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
29 Jul 2025	Deven Choksey	Sell	₹1,300.05	₹1,120	-13.3%	moneycontrol	View
24 Jul 2025	Prabhudas Lilladher	Hold	₹1,247.55	₹1,270	0.3%	moneycontrol	View
12 May 2025	Prabhudas Lilladher	Sell	₹1,195.35	₹1,225	1.4%	moneycontrol	View
27 Jan 2025	KRChoksey	Hold	₹1,197.4	₹1,245	3.9%	moneycontrol	View
24 Jan 2025	Motilal Oswal	Hold	₹1,224.7	₹1,330	8.6%	moneycontrol	View
24 Jan 2025	Prabhudas Lilladher	Sell	₹1,224.7	₹1,335	9%	moneycontrol	View
24 Jan 2025	Emkay Global Financial Services	Sell	₹1,224.7	₹1,150	-6%	moneycontrol	View
06 Nov 2024	KRChoksey	Hold	₹1,303	₹1,329	8.2%	moneycontrol	View
06 Nov 2024	ICICI Securities	Hold	₹1,303	₹1,270	3.4%	moneycontrol	View
06 Nov 2024	Emkay Global Financial Services	Sell	₹1,303	₹1,070	-12.8%	moneycontrol	View
05 Nov 2024	Motilal Oswal	Hold	₹1,272.55	₹1,390	13.1%	moneycontrol	View
28 Jul 2024	ICICI Securities	Sell	₹1,378.43	₹6,350	418.5%	moneycontrol	View
09 May 2024	Motilal Oswal	Hold	₹1,175.81	₹6,070	395.7%	moneycontrol	View
01 Apr 2024	Sharekhan	Buy	₹1,250.17	₹6,537	433.8%	moneycontrol	View
01 Feb 2024	KRChoksey	Hold	₹1,197.97	₹6,460	427.5%	moneycontrol	View
31 Jan 2024	Motilal Oswal	Hold	₹1,224.29	₹5,540	352.4%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	NA	NA	NA	NA	0
DR.REDDYS LABORATORIES LTD.	88624.0	14099.0	85721.0	17.02	1,04,585	18.4
Mankind Pharma Limited	26055.8	4127.6	25413.6	9.99	102484	54.2
Zydus Lifesciences Limited	27454.0	3847.0	25883.0	3.82	98108	21.1

Peer Comparison Chart

About DRREDDYS LABORATORIES

Dr. Reddy's Laboratories Ltd.,, with Security Code 500124, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Company Updates

Latest News

Is Dr Reddys Laboratories Limited a Hybrid Growth Value Stock Worth Holding - Price Volatility Patterns & AI Powered Trading Signals

(28 Sep 2025)

【Market Movement】✌️ Don't waste time on hype — our proven track record of 200%+ gainers speaks for itself. Join and experience the results.

Why Dr Reddys Laboratories Limited Stock May Be a Hidden Gem in YEAR - Breakout Stock Watch & Get Free Expert Trading Recommendations

(28 Sep 2025)

【Investor Updates】✌️ Real-time global market indices and futures data to assist in capturing market opportunities and achieving stable...

Sun Pharma, Cipla or Dr Reddy's: Which pharma major is most vulnerable to Trump's 100% tariff

(26 Sep 2025)

President Trump's imposition of 100% tariffs on branded drugs has shaken Indian pharma companies, impacting stocks like Sun Pharma, Cipla,...

Dr Reddy's Labs appoints Gayatri Prabhu as Head Digital Marketing (Emerging Markets)

(26 Sep 2025)

Hyderabad: Dr Reddy's Labs has appointed Gayatri Prabhu as Head Digital Marketing (Emerging Markets).Gayatri is a result-driven Digital...

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

(26 Sep 2025)

Pharma shares Crash Today - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US...

Cipla, Zydus, Dr Reddy’s, and More Pharma Shares Plunge As Trump Imposes New 100% Tariff; Check Details

(26 Sep 2025)

These early losses reflect investor concerns about the recent tariff announcements impacting the pharmaceutical sector., Markets, Times Now.

Quarterly Table

Standalone Consolidated

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	3,897.6	4,554.0	5,437.3	4,838.7	4,103.0	5,104.8	5,841.2	6,696.3	5,015.0	5,562.9
Expenses	3,222.5	3,492.9	3,209.6	3,209.6	3,446.7	3,726.2	3,888.2	3,974.7	3,822.6	4,119.9
Operating Profit	675.1	1,061.1	2,227.7	1,629.1	656.3	1,378.6	1,953.0	2,721.6	1,192.4	1,443.0
OPM %	17.32%	23.3%	40.97%	33.67%	16%	27.01%	33.43%	40.64%	23.78%	25.94%
Other Income	51.4	114.8	233.6	223.1	227.6	212.7	217.8	207.6	235.4	414.4
Interest	2.8	2.6	4.5	5.8	5.6	5.9	7.1	28.4	43.3	31.1
Depreciation	238.8	236.7	237.2	245.8	246.4	246.2	249.8	260.0	265.1	264.5
Profit before tax	484.9	936.6	2,219.6	1,600.6	631.9	1,339.2	1,913.9	2,640.8	1,119.4	1,561.8
Tax %	-33.1%	-28.2%	-26.1%	-25.5%	-24.8%	-22.7%	26%	-28.7%	-24.1%	-23.1%
Net Profit	324.6	672.4	1,639.4	1,192.6	475.2	1,034.8	1,417.2	1,882.1	849.4	1,200.7
EPS in Rs	3.9	8.08	19.69	14.31	5.7	12.41	16.99	22.56	10.18	0

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	6,315.2	6,757.9	6,902.6	7,236.8	7,113.8	7,696.1	8,038.2	8,381.2	8,528.4	8,572.1
Expenses	4,781.3	4,695.8	4,894.3	5,213.7	5,282.6	5,566.2	5,961.7	6,108.2	6,530.5	6,398.5
Operating Profit	1,533.9	2,062.1	2,008.3	2,023.1	1,831.2	2,129.9	2,076.5	2,273.0	1,997.9	2,173.6
OPM %	24.29%	30.51%	29.09%	27.96%	25.74%	27.68%	25.83%	27.12%	23.43%	25.36%
Other Income	138.5	174.0	315.0	216.2	197.5	187.2	307.5	150.2	522.1	290.3
Interest	35.4	37.1	35.3	39.4	59.3	59.8	75.7	81.7	65.6	83.0
Depreciation	315.5	353.3	375.5	373.5	367.7	380.6	397.0	471.4	454.7	476.1
Profit before tax	1,321.5	1,845.7	1,912.5	1,826.4	1,601.7	1,876.7	1,911.3	1,870.1	1,999.7	1,904.8
Tax %	-27.9%	-24.1%	-22.7%	-24.5%	-18.4%	-26.1%	30.1%	-25.1%	-20.9%	26%
Net Profit	960.1	1,405.0	1,482.2	1,380.9	1,309.8	1,392.4	1,341.9	1,404.2	1,586.7	1,409.9
EPS in Rs	11.54	16.87	17.78	16.56	15.71	16.7	15.05	16.94	0	17.02

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	9%
5 Years:	14%
3 Years:	17%
TTM:	19%

Compounded Profit Growth
10 Years:	13%
5 Years:	13%
3 Years:	49%
TTM:	25%

Stock Price CAGR
10 Years:	6%
5 Years:	9%
3 Years:	12%
1 Year:	4%

Compounded Sales Growth
10 Years:	8%
5 Years:	13%
3 Years:	15%
TTM:	17%

Compounded Profit Growth
10 Years:	9%
5 Years:	23%
3 Years:	39%
TTM:	3%

Stock Price CAGR
10 Years:	6%
5 Years:	9%
3 Years:	12%
1 Year:	4%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Company Updates

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

DRREDDYS LABORATORIES

DRREDDYS LABORATORIES

DRREDDYS LABORATORIES - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About DRREDDYS LABORATORIES

Company Updates

Latest News

Is Dr Reddys Laboratories Limited a Hybrid Growth Value Stock Worth Holding - Price Volatility Patterns & AI Powered Trading Signals

Why Dr Reddys Laboratories Limited Stock May Be a Hidden Gem in YEAR - Breakout Stock Watch & Get Free Expert Trading Recommendations

Sun Pharma, Cipla or Dr Reddy's: Which pharma major is most vulnerable to Trump's 100% tariff

Dr Reddy's Labs appoints Gayatri Prabhu as Head Digital Marketing (Emerging Markets)

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Cipla, Zydus, Dr Reddy’s, and More Pharma Shares Plunge As Trump Imposes New 100% Tariff; Check Details

Sun Pharma, Natco, Dr Reddy's, Laurus Labs Fall Up To 7%; Why Pharma Stocks Crashed After Trump's 100% Tariff?

Dr. Reddy’s Laboratories shares fall over 2% after Trump announces 100% tariff on pharma products

Cipla, Dr. Reddy's, Sun Pharma: Why pharma stocks are falling today

Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories reports negative monthly returns

Dr. Reddy's Laboratories Faces Shift in Market Evaluation Amid Mixed Performance Metrics

Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs

Dr. Reddy’s, Hetero to supply Gilead’s HIV drug Lenacapavir at $40

Indian drugmakers Dr Reddy's, Hetero to sell generic HIV prevention drug for $40 a year

Dr Reddy's Labs receives positive EMA Committee opinion for proposed biosimilar of Prolia, Xgeva

Goldman Sachs Group Inc. Has $2.90 Million Stock Position in Dr. Reddy's Laboratories Ltd $RDY

EMA panel recommends marketing nod for Dr. Reddy’s biosimilar

Dr. Reddy’s Biosimilar Gets Green Light from EMA Committee |

Dr. Reddy’s receives positive CHMP opinion from EMA for AVT03

Goldman Sachs Group Inc. Has $2.90 Million Stock Holdings in Dr. Reddy's Laboratories Ltd $RDY

Goldman Sachs Group Inc. Decreases Position in Dr. Reddy's Laboratories Ltd $RDY

Dr. Reddy's Promoters Transfer 20.58% Shares to Family Trusts

Regulatory Affairs Specialist Jobs For Life Sciences at Dr. Reddy’s Laboratories | Apply Now

Stocks To Watch: Dr Reddys Labs, Mobikwik, Kfin Tech, PC Jeweller, Biocon

Rhumbline Advisers Cuts Stake in Dr. Reddy's Laboratories Ltd $RDY

Parallel Advisors LLC Acquires 29,375 Shares of Dr. Reddy's Laboratories Ltd $RDY

Dr Reddys Lab launches novel molecule, Tegoprazan

Weight-loss drugs: Indian giants Dr Reddy’s to Macleods start preparing for Ozempic patent expiry

Dr Reddy's launches 'Tegoprazan' in India for acid peptic diseases

Acadian Asset Management LLC Has $19.40 Million Position in Dr. Reddy's Laboratories Ltd $RDY

Dr Reddys Labs shares fall 1.21% on Monday, among top losers on Nifty 50

Dr Reddy’s launches new acidity drug tegoprazan in India

Dr. Reddy’s launches new drug for acid peptic disease; check details

Dr. Reddy’s introduces Korean firm HK inno.N’s APD drug Tegoprazan in India

Stocks to Watch Today: Apollo Hospitals, Dr Reddys Labs, Tata Tech, Shakti Pumps, Alembic Pharma, Diamond...

Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations

US FDA Issues Form 483 With Five Observations at Dr Reddy’s Biologics Facility

Top stocks in news: Dr Reddys, Apollo Hospital, Adani Power, Tata Tech, RailTel, Info Edge

Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, Torrent Pharma et al: Parsing through the pharma value chain

U.S. FDA issues 5 observations to Dr. Reddy’s biologics manufacturing facility in Hyderabad

Dr Reddy’s Bachupally facility gets 5 observations from US FDA inspection

Dr Reddys Labs gets 5 observations from USFDA for Bachupally facility

Recent uptick might appease Dr. Reddy's Laboratories Limited (NSE:DRREDDY) institutional owners after losing 1.9% over the past year

Dr. Reddys Acquires J&Js Stugeron Portfolio For Rs 445 Crore, Enters Anti-Vertigo Segment

Stock Radar: Dr Reddy’s stock breaks out from 5-week consolidation in September; check target & stop loss

Dr. Reddy's shares in focus after $50.5 million acquisition marking anti-vertigo foray

Stocks to Watch Today: Dr Reddys Labs, Jupiter Wagons, Rail Vikas Nigam, Highway Infrastructure, Mazagon...

Dr Reddy's shares in focus on USD $50.5 million acquisition announcement

Markets set to open flat amid mixed global cues; Infosys, Tata Motors, Dr Reddy’s shares in focus today

Dr. Reddy's acquires J&J's Stugeron brand for $50.5 million

Hyderabad-based Dr Reddy’s inks pact with Johnson & Johnson to acquire vertigo treatment brand

Dr Reddy’s Shares Trading Flat After $50.5M Anti-Vertigo Acquisition

Dr Reddy’s Laboratories shares fall nearly 2% on acquiring Johnson & Johnson’s Stugeron brand

Dr. Reddy’s Buys STUGERON Portfolio for $50.5M Expansion

Dr Reddys Laboratories shares rise 2.17% in early trade

Buy Dr. Reddy's Laboratories at Rs 1291.3 | Upside: 8% - Market Trading Guide: Buy Adani Ports, Dr Reddy’s and 5 smallcap stocks on Wednesday for short term gains up to 11%

Religare Broking's weekly stock picks: 'Buy' Ashok Leyland, Dr Reddy's & Havells

Dr Reddy's Labs UK facility flagged with 7 USFDA observations

Stock Alert: Adani Power, Lupin, Dr Reddy's Laboratories, Imagicaaworld Entertainment, Kaynes Technology India

Royal Bank of Canada Has $119.38 Million Holdings in Dr. Reddy's Laboratories Ltd $RDY

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations

Dr. Reddy's Laboratories slides Tuesday, underperforms competitors

Opening Bell: Sensex up by 200 points, Nifty at 24,684; shares of Reliance Industries lead, Dr Reddy’s lags

Top gainers and losers on September 2: Dr. Reddy’s Lab falls 2%, Tata Consumer, Nestle surge 2%; check list

Dr. Reddy's Laboratories CHRO Archana Bhaskar resigns

Jump Financial LLC Increases Holdings in Dr. Reddy's Laboratories Ltd $RDY

Dr Reddy's Labs CHRO Archana Bhaskar resigns

Association of Physicians of India-MSC in collaboration with Dr. Reddy’s announces August 29 as National...

API MSC, Dr. Reddy's Announce August 29 as National Cough Day